Format
Sort by

Send to:

Choose Destination

Results: 4

1.

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, Fuchs J, Koblin B, Kim DH, Joseph P, Keefer MC, Baden LR, Eldridge J, Boyer J, Sherwat A, Cardinali M, Allen M, Pensiero M, Butler C, Khan AS, Yan J, Sardesai NY, Kublin JG, Weiner DB; NIAID HIV Vaccine Trials Network.

J Infect Dis. 2013 Sep 1;208(5):818-29. doi: 10.1093/infdis/jit236. Epub 2013 Jul 8.

2.

Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.

Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, Ottinger J, Ferarri G, Montefiori DC, Stablein D, Smith C, Ginsberg R, Eldridge J, Duerr A, Fast P, Haynes BF; AIDS Vaccine Evaluation Group.

PLoS One. 2010 Aug 10;5(8):e11995. doi: 10.1371/journal.pone.0011995.

3.

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.

Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR; NIAID HIV Vaccine Trials Network (HVTN) Vaccine-Induced Seropositivity (VISP) Task Force.

JAMA. 2010 Jul 21;304(3):275-83. doi: 10.1001/jama.2010.926.

4.

Trial-related discrimination in HIV vaccine clinical trials.

Allen M, Israel H, Rybczyk K, Pugliese MA, Loughran K, Wagner L, Erb S.

AIDS Res Hum Retroviruses. 2001 May 20;17(8):667-74.

PMID:
11429107
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk